Testing mylife CamAPS FX system in type 1 diabetes patients in France
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new automated insulin delivery system (mylife CamAPS FX) for people with type 1 diabetes. It aims to see how well the system works when paired with a Dexcom G6 continuous glucose monitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 diabetes and have been using a Dexcom or Abbott Libre glucose sensor for at least 14 days, with the sensor working at least 70% of the time.
- Your diabetes doctor has decided to start you on the mylife CamAPS FX hybrid closed-loop system.
- You are an adult (or a child whose parents agree) and can understand French to complete online questionnaires.
- You are not currently using any other closed-loop or automated insulin delivery system (including DIY systems) and have not used one in the last 6 months.
- You do not have any skin problems at the sensor or pump site, unstable diabetic retinopathy needing laser treatment, or any other condition that would affect blood sugar control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an automated insulin delivery system that combines a pump and a continuous glucose monitor to help keep blood sugar levels stable. People with type 1 diabetes may have better glucose control and quality of life while using this system.
This study tests a new experimental automated insulin delivery system for people with type 1 or type 2 diabetes who already use a specific insulin pump (MiniMed 780G with Simplera Sync sensor). The goal is to see if the new system is safe and works well to help manage blood sugar.
This trial compares your current insulin pump therapy with a fully automated closed-loop system (artificial pancreas) that adjusts insulin using a smartphone algorithm. It aims to see which method works better for managing blood sugar levels in people with type 2 diabetes.
This real-world study looks at how the Control-IQ system (an automated insulin pump with a continuous glucose monitor) affects blood sugar control and quality of life for people with type 1 diabetes in France. If you join, you will use the system as usual and fill out some questionnaires for one year.
This trial tests a 'closed-loop' system that automatically adjusts insulin delivery for people with type 2 diabetes. If you already use insulin and certain diabetes medications, this study could help see if a smart insulin pump improves blood sugar control.
This study tests a smart insulin pump and continuous glucose monitor system that adjusts insulin automatically and uses behavior support to improve blood sugar control. It's for people with type 1 diabetes who have used an approved automated insulin delivery system recently and are willing to use study devices.
Hear when a new Diabetes Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.